Bristol-Myers Halts Virus-Drug Research, Cuts 100 Employees
This article is for subscribers only.
Bristol-Myers Squibb Co. is ending discovery research on drugs to treat viruses and dismissing about 100 employees, focusing instead on building its pipeline of cancer treatments.
The company will shut down two sites as it halts early-stage virology research, including efforts in hepatitis B and HIV, Bristol-Myers said in a statement Thursday. The change won’t affect ongoing drug development or treatments currently for sale.